Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs

Patent Law

: Patent Docs

FTC Disapproves of "Pay-for-Delay" Drug Deals

By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry

By Kevin E. Noonan -- Last month, the Federal Trade Commission released a report about so-called "pay for delay" arrangements, agreements between branded pharmaceutical companies and generic drug companies that delay entry of generic versions of branded drugs. The FTC's position is clear from the title of the Report: "Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions." The Report, by FTC staffers from the Bureau of Competition, Bureau of Economics, and Office of Policy Planning, describes these agreements as "win-win" for the companies, by permitting brand-name drug prices to stay high while giving generic companies a share of the high...

Full post as published by Patent Docs on February 16, 2010 (boomark / email).